Reported 6 months ago
Novo Nordisk's type 2 diabetes medicine, Ozempic, has shown promising results in treating Chronic Kidney Disease (CKD) in high-risk patients with type 2 diabetes. A recent phase 3 clinical trial revealed that patients who received semaglutide, the active ingredient in Ozempic, had a 24% lower risk of major kidney disease events and an 18% lower risk of major cardiovascular events compared to those who received a placebo. These results indicate a high probability of Ozempic receiving FDA approval for treating CKD, leading to potential market expansion and revenue growth for Novo Nordisk.
Source: YAHOO